GALAPAGOS BIOPHARMA NORWAY AS
0167 OSLO
Return on Equity
83,83Â %
Current Ratio
4,42
Debt-to-Equity Ratio
8,2
| Key figures (NOK) | 2022 | |
|---|---|---|
| Revenue | 5Â 826Â 000 | |
| Net Income | 394Â 000 | |
| Total Assets | 5Â 590Â 000 | |
| Total Equity | 470Â 000 |
| Income (NOK) | 2022 | |
|---|---|---|
| Revenue | 5Â 826Â 000 | |
| Expenditure | 5Â 069Â 000 | |
| Operating Profit | 757Â 000 | |
| Financial Income | 161Â 000 | |
| Financial Costs | 413Â 000 | |
| Financial Balance | −252 000 | |
| Earnings Before Tax | 506Â 000 | |
| Tax | 111Â 000 | |
| Net Income | 394Â 000 |
| Balance (NOK) | 2022 | |
|---|---|---|
| Total Fixed Assets | 0 | |
| Total Current Assets | 5Â 590Â 000 | |
| Total Assets | 5Â 590Â 000 | |
| Total Retained Equity | 440Â 000 | |
| Total Equity | 470Â 000 | |
| Total Long-Term Debt | 3Â 856Â 000 | |
| Total Current Debt | 1Â 264Â 000 | |
| Total Equity and Debt | 5Â 590Â 000 |
| Cash flow (NOK) | 2022 | |
|---|---|---|
| Sales Income | 5Â 826Â 000 | |
| Other Income | 0 | |
| Revenue | 5Â 826Â 000 | |
| Cost of Goods Sold | 0 | |
| Salary Costs | 2Â 161Â 000 | |
| Depreciation | 0 | |
| Impairment | 0 | |
| Expenditure | 5Â 069Â 000 | |
| Operating Profit | 757Â 000 | |
| Financial Income | 161Â 000 | |
| Financial Costs | 413Â 000 | |
| Financial Balance | −252 000 | |
| Dividends | 0 | |
| Net Income | 394Â 000 |
| Balance details (NOK) | 2022 | |
|---|---|---|
| Goodwill | 0 | |
| Total Intangible Assets | 0 | |
| Real Eastate | 0 | |
| Machinery and Plant Facilities | 0 | |
| Fixtures | 0 | |
| Total Tangible Assets | 0 | |
| Total Fiancial Fixed Assets | 0 | |
| Total Fixed Assets | 0 | |
| Stock | 0 | |
| Total Investments | 0 | |
| Cash, Bank | 0 | |
| Total Current Assets | 5Â 590Â 000 | |
| Total Assets | 5Â 590Â 000 | |
| Total Equity | 470Â 000 | |
| Short-Term Group Debt | 0 | |
| Total Long-Term Debt | 3Â 856Â 000 | |
| Creditors | 0 | |
| Unpaid Taxes | 13Â 000 | |
| Dividends | 0 | |
| Other Current Debt | 1Â 140Â 000 | |
| Total Current Debt | 1Â 264Â 000 | |
| Total Equity and Debt | 5Â 590Â 000 |
| Financial indicators | 2022 | |
|---|---|---|
| Return on Equity | 83,83Â % | |
| Debt-to-Equity Ratio | 8,2 | |
| Operating Profit Margin | 12,99Â % | |
| Current Ratio | 4,42 | |
| Quick Ratio | 4,42 | |
| Equity Ratio | 0,08 | |
| Gross Profit Margin | 100Â % |
Rotate your device to see the full table